Skip to content

PDCD4/PPARα axis regulates oxidative stress-mediated microvascular endothelial injury in myocardial ischemia-reperfusion.

Aug 2026 · Cellular Signalling · Vol 148, pp. 112786 · 0 citations · 43 references
Medicine

Abstract

Cardiac microvascular endothelial cell (CMEC) injury is a primary driver of microvascular obstruction and the no-reflow phenomenon during myocardial ischemia/reperfusion (I/R). While Programmed Cell Death 4 (PDCD4) is known to exacerbate cardiovascular diseases, its precise role and regulatory mechanisms in CMEC barrier dysfunction and inflammatory adhesion during I/R remain unclear. In this study, we demonstrate that PDCD4 deletion significantly mitigates I/R-induced cardiac dysfunction, reduces infarct size, and preserves microvascular ultrastructure in mice. In vitro experiments using a hypoxia/reoxygenation (H/R) model revealed that PDCD4 knockdown preserves CMEC viability, suppresses apoptosis, and maintains endothelial barrier integrity by restoring tight junction proteins (ZO-1, Claudin-1, and Occludin). Furthermore, PDCD4 inhibition significantly reduced pathological permeability and attenuated the adhesion of neutrophils and macrophages by downregulating ICAM-1. Mechanistically, PDCD4 directly interacts with Peroxisome Proliferator-Activated Receptor alpha (PPARα) at the protein level and restricts its protective antioxidant function. Co-immunoprecipitation and immunofluorescence supported this interaction. Silencing PDCD4 restored PPARα-dependent antioxidant responses, leading to a marked reduction in oxidative stress (decreased ROS and MDA, increased SOD). Crucially, double-knockdown rescue experiments confirmed that the protective effects of PDCD4 depletion against H/R-induced apoptosis, barrier disruption, and inflammatory adhesion were largely abolished upon concurrent PPARα silencing. These findings establish that PDCD4 exacerbates I/R-induced CMEC injury by binding to and inhibiting PPARα-mediated antioxidant homeostasis. Targeting the PDCD4-PPARα interaction axis presents a promising therapeutic strategy to prevent microvascular dysfunction and improve outcomes following acute myocardial infarction.

View source

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.